Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction - PubMed (original) (raw)
Comparative Study
Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction
Stephen E Kimmel et al. Ann Intern Med. 2005.
Free article
Abstract
Background: Studies have postulated that cyclooxygenase-2 (COX-2) selective inhibitors affect cardiovascular risk through various mechanisms. Some of these mechanisms could increase risk (for example, inhibition of prostacyclin production), and some could decrease risk (for example, inhibition of inflammation).
Objective: To determine the effect of COX-2 inhibitors on risk for nonfatal myocardial infarction (MI).
Design: Case-control study.
Setting: 36 hospitals in a 5-county area.
Participants: 1718 case-patients with a first, nonfatal MI admitted to these hospitals and 6800 controls randomly selected from the same counties.
Measurements: Self-reported medication use assessed through telephone interviews.
Results: The adjusted odds ratio for MI among celecoxib users, relative to persons who did not use nonaspirin nonsteroidal anti-inflammatory drugs (NSAIDs), was 0.43 (95% CI, 0.23 to 0.79) compared with 1.16 (CI, 0.70 to 1.93) among rofecoxib users. The use of rofecoxib was associated with a statistically significant higher odds of MI compared with the use of celecoxib (adjusted odds ratio for rofecoxib vs. celecoxib, 2.72 [CI, 1.24 to 5.95]; P = 0.01). Nonselective NSAIDs were associated with a reduced odds of nonfatal MI relative to nonusers. Comparisons of COX-2 inhibitors with nonselective NSAIDs were the following: rofecoxib versus naproxen (odds ratio, 3.39 [CI, 1.37 to 8.40]) and celecoxib versus ibuprofen or diclofenac (odds ratio, 0.77 [CI, 0.40 to 1.48]).
Limitations: The possibility of recall bias and uncontrolled confounding in this observational study limit the ability to make definitive conclusions. The association of celecoxib with a lower odds of MI could have occurred by chance. Only about 50% of eligible participants completed telephone interviews.
Conclusion: Celecoxib and rofecoxib were associated with different odds of MI. Cardiovascular effects among the COX-2 inhibitors seem different, but further studies, preferably randomized trials, are needed to fully understand the spectrum of effects of COX-2 inhibitors and potential differences among them.
Comment in
- Cardiovascular risks of cyclooxygenase-2 inhibitors: where we stand now.
Finckh A, Aronson MD. Finckh A, et al. Ann Intern Med. 2005 Feb 1;142(3):212-4. doi: 10.7326/0003-4819-142-3-200502010-00013. Ann Intern Med. 2005. PMID: 15684210 No abstract available.
Summary for patients in
- Summaries for patients. Cyclooxygenase-2 inhibitors and heart attacks: varying effects?
[No authors listed] [No authors listed] Ann Intern Med. 2005 Feb 1;142(3):I21. doi: 10.7326/0003-4819-142-3-200502010-00001. Ann Intern Med. 2005. PMID: 15684199 No abstract available.
Similar articles
- Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study.
Johnsen SP, Larsson H, Tarone RE, McLaughlin JK, Nørgård B, Friis S, Sørensen HT. Johnsen SP, et al. Arch Intern Med. 2005 May 9;165(9):978-84. doi: 10.1001/archinte.165.9.978. Arch Intern Med. 2005. PMID: 15883235 - Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction.
Gislason GH, Jacobsen S, Rasmussen JN, Rasmussen S, Buch P, Friberg J, Schramm TK, Abildstrom SZ, Køber L, Madsen M, Torp-Pedersen C. Gislason GH, et al. Circulation. 2006 Jun 27;113(25):2906-13. doi: 10.1161/CIRCULATIONAHA.106.616219. Epub 2006 Jun 19. Circulation. 2006. PMID: 16785336 - Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2.
McGettigan P, Henry D. McGettigan P, et al. JAMA. 2006 Oct 4;296(13):1633-44. doi: 10.1001/jama.296.13.jrv60011. Epub 2006 Sep 12. JAMA. 2006. PMID: 16968831 Review. - Selective cyclo-oxygenase-2 inhibitors and myocardial infarction: how strong is the link?
Howes LG, Krum H. Howes LG, et al. Drug Saf. 2002;25(12):829-35. doi: 10.2165/00002018-200225120-00001. Drug Saf. 2002. PMID: 12241124 Review.
Cited by
- The Safety of Celecoxib as an Acute Treatment for Migraine: A Narrative Review.
Ailani J, Nahas SJ, Friedman DI, Kunkel T. Ailani J, et al. Pain Ther. 2023 Jun;12(3):655-669. doi: 10.1007/s40122-023-00501-5. Epub 2023 Apr 24. Pain Ther. 2023. PMID: 37093356 Free PMC article. Review. - Preservation of Post-Infarction Cardiac Structure and Function via Long-Term Oral Formyl Peptide Receptor Agonist Treatment.
García RA, Ito BR, Lupisella JA, Carson NA, Hsu MY, Fernando G, Heroux M, Bouvier M, Dierks E, Kick EK, Gordon DA, Chen J, Mintier G, Carrier M, St-Onge S, Shah H, Towne J, Bucardo MS, Ma X, Ryan CS, Wurtz NR, Ostrowski J, Villarreal FJ. García RA, et al. JACC Basic Transl Sci. 2019 Nov 13;4(8):905-920. doi: 10.1016/j.jacbts.2019.07.005. eCollection 2019 Dec. JACC Basic Transl Sci. 2019. PMID: 31909300 Free PMC article. - (Re) Solving Repair After Myocardial Infarction.
Leoni G, Soehnlein O. Leoni G, et al. Front Pharmacol. 2018 Nov 26;9:1342. doi: 10.3389/fphar.2018.01342. eCollection 2018. Front Pharmacol. 2018. PMID: 30534069 Free PMC article. - Nonsteroidal anti-inflammatory drug choice and adverse outcomes in clopidogrel users: A retrospective cohort study.
Nam YH, Brensinger CM, Bilker WB, Leonard CE, Kasner SE, Grosser T, Li X, Hennessy S. Nam YH, et al. PLoS One. 2018 Mar 14;13(3):e0193800. doi: 10.1371/journal.pone.0193800. eCollection 2018. PLoS One. 2018. PMID: 29538453 Free PMC article. - The effect of anti-rheumatic medications for coronary artery diseases risk in patients with rheumatoid arthritis might be changed over time: A nationwide population-based cohort study.
Hung YM, Lin L, Chen CM, Chiou JY, Wang YH, Wang PY, Wei JC. Hung YM, et al. PLoS One. 2017 Jun 28;12(6):e0179081. doi: 10.1371/journal.pone.0179081. eCollection 2017. PLoS One. 2017. PMID: 28658301 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials